- Surmodics, Inc. (SRDX, Financial) to announce Q2 fiscal 2025 financial results on April 30, 2025.
- No live webcast or conference call due to pending acquisition by GTCR.
- Surmodics specializes in medical device and in vitro diagnostic technologies.
Surmodics, Inc. (SRDX), a prominent figure in the realm of medical device and in vitro diagnostic technologies, has scheduled the release of its second quarter financial results for fiscal year 2025 on April 30, 2025, prior to the market opening. The company will not conduct a live webcast or conference call for the announcement due to the ongoing acquisition process by GTCR.
Headquartered in Eden Prairie, Minnesota, Surmodics focuses on performance coating technologies for intravascular medical devices and components for in vitro diagnostic tests. The company's strategic emphasis on creating innovative vascular intervention medical devices aims to meet unmet clinical needs through advanced surface modification and drug-delivery coating technologies.
Recently, Surmodics has been in the news for developments such as the publication of the TRANSCEND trial, highlighting the drug-delivery efficiency of its SurVeil™ Drug-Coated Balloon, and the commercial release of the Pounce™ XL Thrombectomy System, designed for non-surgical clot removal. These innovations are part of Surmodics' mission to enhance disease detection and treatment.
